Doximity (NASDAQ: DOCS) plunged 23.6% to $17.86 on May 14, 2026, the morning after the digital-health platform reported fiscal fourth-quarter results that beat revenue estimates but exposed a sharp slowdown in growth, an evaporating operating margin, and a forward outlook that landed well below Wall Street expectations. The selloff erased roughly $1 billion of market value and dropped the stock to a fresh 52-week low of $17.15 intraday, capping a brutal year that has seen DOCS fall about 60% from its 52-week high of $76.51.
The damage was compounded by a wave of analyst downgrades and target cuts, as the sellside rapidly capitulated on a name that had been a Street favorite for its high gross margin and clean profitability profile.
The Quarter: Growth Decelerates, Margin Falls Off a Cliff
Doximity, whose fiscal year ends in March, reported fourth-quarter revenue of $145.4 million, up 5.1% year over year — a notable deceleration from the double-digit growth investors had become accustomed to. For the full fiscal 2026 year, revenue grew 13.1% to $644.9 million, but the trajectory matters: Q4 was the slowest quarter of the year, and management’s guidance suggests that pace continues into fiscal 2027.
The bigger shock was on the margin line. Q4 operating income fell to $24.8 million from $52.4 million a year earlier, with operating margin compressing to 17.1% from 35.2%. Net income dropped 69% to $19.1 million. Gross margin held at a healthy 86.7%, so the squeeze is entirely on operating spend — the company is investing more in product, sales, and AI capabilities at exactly the moment growth has slowed.
| Metric | Q4 FY2026 | Q4 FY2025 | YoY Change |
|---|---|---|---|
| Revenue | $145.4M | $138.3M | +5.1% |
| Gross margin | 86.7% | 87.4% | -70 bps |
| Operating income | $24.8M | $52.4M | -52.6% |
| Operating margin | 17.1% | 35.2% | -1,810 bps |
| Net income | $19.1M | $62.4M | -69.4% |
| Diluted EPS (GAAP) | $0.10 | $0.33 | -69.7% |
The Guide: A Step Down That Snapped the Bull Case
The number that really triggered the sell-off was the fiscal 2027 outlook. Doximity guided FY27 revenue to $664–$676 million, against Street consensus of about $697.5 million. The midpoint implies just 3.9% top-line growth — a striking step down from FY26’s 13.1% pace, and a long way from the high-teens cadence that made Doximity a darling.
First-quarter FY27 guidance landed at $151–$152 million, slightly below the $153.3 million consensus, and the adjusted EBITDA range of $323–$335 million for the year embeds incremental investment that further pressures profitability versus the model investors were running.
Management cited two main culprits in the call: softer demand from pharmaceutical-marketing customers, and a deliberate ramp in AI-product spend as Doximity layers generative tools (clinical drafting assistants, AI-powered scheduling) onto its core physician network. The pitch is that AI investment now buys re-acceleration later. The market, looking at the same chart of decelerating growth and shrinking margins, did not give the company the benefit of the doubt.
The Sellside Capitulates
By Thursday morning, at least six major brokers had cut price targets, and several pulled their Buy ratings entirely. The downgrade slate was unusually severe for a single-quarter print:
| Broker | Action | New PT | Prior PT |
|---|---|---|---|
| Wells Fargo | Downgrade to Equal Weight | $18 | $32 |
| Baird | Downgrade to Neutral | $18 | $40 |
| Jefferies | Downgrade to Hold | $19 | $51 |
| BMO Capital | PT cut | $20 | $25 |
| JPMorgan | PT cut | $28 | $33 |
| Morgan Stanley | PT cut | $35 | $49 |
The blended consensus target now sits near $35, still roughly twice the current price — but the dispersion is telling. The most bearish desks have effectively marked DOCS at today’s tape, with $18–$19 targets, while the more constructive shops are anchoring closer to the mid-$30s on the bet that AI spend pays off in fiscal 2028.
What Actually Changed in the Story
Doximity has spent years arguing it occupies a defensible niche: a registered network of more than two million U.S. healthcare professionals, monetized through pharmaceutical marketing, hiring services, and telehealth tools. That thesis isn’t broken. But three specific things did shift this quarter:
- Pharma-marketing budgets cooled. Management flagged longer sales cycles and softer ad demand from big pharma customers, a category that drives the majority of high-margin revenue.
- AI capex hit the P&L without commensurate revenue. Operating margin dropped roughly 18 points year-over-year in the quarter, largely from product and engineering investment to build AI agents on top of the network.
- The “rule of 40” math broke. A 4% growth guide plus a ~50% adjusted EBITDA margin keeps DOCS above the rule of 40 in name, but for a stock that traded as a high-growth name, the framing now looks much more like a mature SaaS asset that needs to defend its multiple.
The natural comparison investors will draw is to other healthcare-tech names that built scale, leveled off, and then had to re-rate. DOCS now trades at roughly 18x trailing GAAP EPS, a multiple that no longer prices in re-acceleration. The bull case from here is a second-half FY27 recovery in pharma demand and visible monetization of the AI features. The bear case is that today’s guide is itself optimistic and the next two prints walk it lower.
The Setup From Here
At $17.86 the stock is trading inside its 52-week low. Three things will define the next leg:
- Q1 FY27 print in August. Management has set the bar at $151–$152 million. A beat-and-raise resets sentiment; an in-line print with maintained full-year guide keeps the stock range-bound; a cut would be a fresh down-leg.
- AI-product traction. Doximity’s pitch hinges on its clinical AI assistant and ambient documentation tools gaining real share against Abridge, Suki, and the in-house tools major EHR vendors are shipping. Any disclosed customer or seat numbers will move the stock.
- Pharma-ad cycle. Beyond Doximity’s own demand commentary, watch the larger digital-ad commentary from Meta and Alphabet, and the pharma-ad-specific commentary from companies like Veeva and IQVIA, as a read-through on whether the slowdown is company-specific or industry-wide.
For now, Doximity goes into the books as the kind of compounding-margin-story-stock that gets harshly re-rated the moment growth stalls. The healthcare network is intact. The narrative isn’t.
Sources
- StockAnalysis.com — Doximity (DOCS) overview and analyst targets
- StockAnalysis.com — Doximity annual income statement
- StockAnalysis.com — Doximity quarterly financials
- Doximity Investor Relations
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.